Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • S&P 500

    5,248.49
    +44.91 (+0.86%)
     
  • Dow

    39,760.08
    +477.75 (+1.22%)
     
  • Nasdaq

    16,399.52
    +83.82 (+0.51%)
     
  • Bitcoin USD

    70,525.34
    +487.73 (+0.70%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,970.20
    +38.22 (+0.48%)
     
  • Gold

    2,218.20
    +5.50 (+0.25%)
     
  • Crude Oil

    81.85
    +0.50 (+0.61%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Nikkei

    40,168.07
    -594.66 (-1.46%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE Bursa Malaysia

    1,530.60
    -7.82 (-0.51%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Why pharmaceutical segment brings headache to Singapore’s manufacturing output

It has contracted for three consecutive months now.

The city-state's industrial production might have posted a much higher improvement if not because of the flailing biomedical manufacturing cluster.

According to a report published by UOB, manufacturing output grew an unnoticeably 0.1% in August, inching up from -3.5% contraction in July. One of the key reasons for the weak overall activity is the slow -8.4% pace in biomedical manufacturing output.

"Excluding that cluster, IP expanded 2.3% YoY," UOB said.

The said segment has been contracting for the past two months before August.

"The lower production of active pharmaceutical ingredients and biological products had caused a 14.1% YoY decline in pharma output," the note stated.

ADVERTISEMENT

This had offset 12.1% YoY expansion in the medical technology segment.

UOB noted that weaknesses were also seen in the general manufacturing cluster as well as the transport engineering cluster.



More From Singapore Business Review